Efficient discovery of anti-inflammatory small molecule combinations using evolutionary computing

The control of biochemical fluxes is distributed and to perturb complex intracellular networks effectively it is often necessary to modulate several steps simultaneously. However, the number of possible permutations leads to a combinatorial explosion in the number of experiments that would have to be performed in a complete analysis. We used a multi-objective evolutionary algorithm (EA) to optimize reagent combinations from a dynamic chemical library of 33 compounds with established or predicted targets in the regulatory network controlling IL-1β expression. The EA converged on excellent solutions within 11 generations during which we studied just 550 combinations out of the potential search space of ~ 9 billion. The top five reagents with the greatest contribution to combinatorial effects throughout the EA were then optimized pairwise. A p38 MAPK inhibitor with either an inhibitor of IκB kinase or a chelator of poorly liganded iron yielded synergistic inhibition of macrophage IL-1β expression. Evolutionary searches provide a powerful and general approach to the discovery of novel combinations of pharmacological agents with potentially greater therapeutic indices than those of single drugs.

[1]  J. Relton,et al.  Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat , 1992, Brain Research Bulletin.

[2]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[3]  D A Fell,et al.  Physiological control of metabolic flux: the requirement for multisite modulation. , 1995, The Biochemical journal.

[4]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[5]  Zbigniew Michalewicz,et al.  Handbook of Evolutionary Computation , 1997 .

[6]  P. Ponka,et al.  The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. , 2000, Cardiovascular research.

[7]  Y. W. Lee,et al.  Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. , 2000, Immunopharmacology.

[8]  Yong Woo Lee,et al.  Dexamethasone inhibits IL-1β gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-κB/Rel and AP-1 activation , 2000 .

[9]  Evan J. Hughes,et al.  Evolutionary Multi-objective Ranking with Uncertainty and Noise , 2001, EMO.

[10]  David E. Goldberg,et al.  The Design of Innovation: Lessons from and for Competent Genetic Algorithms , 2002 .

[11]  Gary B. Lamont,et al.  Evolutionary Algorithms for Solving Multi-Objective Problems , 2002, Genetic Algorithms and Evolutionary Computation.

[12]  D. Kell,et al.  Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  Eckart Zitzler,et al.  Indicator-Based Selection in Multiobjective Search , 2004, PPSN.

[14]  Joshua D. Knowles,et al.  Closed-loop, multiobjective optimization of analytical instrumentation: gas chromatography/time-of-flight mass spectrometry of the metabolomes of human serum and of yeast fermentations. , 2005, Analytical chemistry.

[15]  Gary B. Lamont,et al.  Evolutionary Algorithms for Solving Multi-Objective Problems (Genetic and Evolutionary Computation) , 2006 .

[16]  H. Kitano,et al.  A comprehensive map of the toll-like receptor signaling network , 2006, Molecular systems biology.

[17]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[18]  Hon Keung Tony Ng,et al.  Statistics: An Introduction Using R , 2006, Technometrics.

[19]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[20]  M. Krams,et al.  Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.

[21]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[22]  Joshua D. Knowles,et al.  Multiobjective Optimization in Bioinformatics and Computational Biology , 2007, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[23]  Kalyanmoy Deb,et al.  Multiobjective Problem Solving from Nature: From Concepts to Applications (Natural Computing Series) , 2008 .

[24]  C. Löfdahl COPD and co‐morbidities, with special emphasis on cardiovascular conditions , 2008, The clinical respiratory journal.

[25]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[26]  R. Sun,et al.  Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm , 2008, Proceedings of the National Academy of Sciences.

[27]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[28]  Kalyanmoy Deb,et al.  Multiobjective Problem Solving from Nature: From Concepts to Applications , 2008, Natural Computing Series.

[29]  Corey Nislow,et al.  Combination chemical genetics. , 2008, Nature chemical biology.

[30]  D. Kell Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases , 2008, BMC Medical Genomics.

[31]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[32]  Joshua D. Knowles Closed-loop evolutionary multiobjective optimization , 2009, IEEE Computational Intelligence Magazine.

[33]  D. Kell,et al.  Array-based evolution of DNA aptamers allows modelling of an explicit sequence-fitness landscape , 2008, Nucleic acids research.

[34]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[35]  Ren Sun,et al.  Integrative systems control approach for reactivating Kaposi's sarcoma-associated herpesvirus (KSHV) with combinatory drugs. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[36]  D. Brough,et al.  Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy , 2009, British journal of pharmacology.

[37]  John A. Tallarico,et al.  Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.

[38]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[39]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[40]  E. Tobinick The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[41]  R. K. Ursem Multi-objective Optimization using Evolutionary Algorithms , 2009 .

[42]  Jeremy E Purvis,et al.  Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli , 2010, Nature Biotechnology.

[43]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[44]  Jorge Cortes,et al.  Systems approaches and algorithms for discovery of combinatorial therapies. , 2009, Wiley interdisciplinary reviews. Systems biology and medicine.

[45]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[46]  G. Firestein,et al.  “Go upstream, young man”: lessons learned from the p38 saga , 2009, Annals of the rheumatic diseases.

[47]  Carl Nathan,et al.  Nonresolving Inflammation , 2010, Cell.

[48]  Joshua D. Knowles,et al.  Evolutionary Optimization on Problems Subject to Changes of Variables , 2010, PPSN.

[49]  J. Pfeilschifter,et al.  SphK1 Regulates Proinflammatory Responses Associated with Endotoxin and Polymicrobial Sepsis , 2010, Science.

[50]  P. Scully,et al.  Plasma Cytokine Profiles in Females With Irritable Bowel Syndrome and Extra-Intestinal Co-Morbidity , 2010, The American Journal of Gastroenterology.

[51]  Douglas B. Kell,et al.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples , 2010, Archives of Toxicology.

[52]  David DeCaprio,et al.  Cheminformatics approaches to analyze diversity in compound screening libraries. , 2010, Current opinion in chemical biology.

[53]  Mike Tyers,et al.  Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. , 2011, Nature chemical biology.

[54]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[55]  Cord Sunderkötter,et al.  An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. , 2011, The Journal of clinical investigation.